Laboratory Products
New Assay Allows Earlier Diagnosis of Impaired Renal Function
Jan 11 2010
Roche is pleased to announce the launch of a new assay for the early assessment of glomerular filtration rate (GFR) in patients with impaired renal function. The Roche Cystatin C assay is more sensitive than creatinine measurements, allowing diagnosis of chronic kidney disease (CKD) at an early stage when therapeutic intervention is possible. Cystatin C is an endogenous substance synthesised by all nucleated cells at a constant rate and filtered freely by the glomerulus. Unlike creatinine, cystatin C levels are not affected by muscle mass, age (below 50), gender or inflammation and it is only eliminated via filtration, making it a convenient and accurate marker for the assessment of GFR.
Studies have suggested that Cystatin C is a more sensitive marker of GFR than creatinine1,2,3. By indicating a reduction in GFR sooner, it is ideal for the assessment of patients in the early stages of CKD and reduces the need to perform invasive determinations of GFR. The Roche Cystatin C assay is promoted for use in the assessment of children (under 4) and patients under the age of 60, for early diagnosis of initially minor kidney damage (for example in diabetes patients). It can also be used in monitoring kidney disease and post transplantation patients, and for dose adjustment of renally excreted drugs. The assay is easy to use, requiring minimal handling, and produces highly precise and sensitive results from a low sample volume (2μl).
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark